Aziz Ouerdani Selected Research

simurosertib

1/2022

Population Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aziz Ouerdani Research Topics

Disease

2	Neoplasms (Cancer) 01/2022 - 01/2016
2	Infections 11/2021 - 01/2019
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022
1	Body Weight (Weight, Body) 01/2022
1	Lung Neoplasms (Lung Cancer) 01/2022
1	Neurofibromatosis 2 (Neurofibromatosis Type II) 01/2016
1	Acoustic Neuroma (Acoustic Neurinoma) 01/2016

Drug/Important Bio-Agent (IBA)

1	simurosertibIBA 01/2022
1	CrizotinibIBA 01/2022
1	brigatinibIBA 01/2022
1	Anaplastic Lymphoma KinaseIBA 01/2022
1	CreatinineIBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	Oxazolidinones (2 Oxazolidone)IBA 11/2021
1	tedizolidIBA 11/2021
1	tedizolid phosphateIBA 11/2021
1	Anti-Bacterial Agents (Antibiotics)IBA 11/2021
1	doravirineIBA 01/2019
1	Reverse Transcriptase InhibitorsIBA 01/2019
1	TOR Serine-Threonine KinasesIBA 01/2016
1	Everolimus FDA Link 01/2016
1	Vascular Endothelial Growth FactorsIBA 01/2016
1	Bevacizumab (Avastin)FDA Link 01/2016